Epithalon

In animals — mice, rats, fruit flies — chronic epithalon extended lifespan by 12 to 24% across multiple studies, and it reactivates telomerase in human fibroblasts in a dish, adding 10 to 15 population doublings. But the clinical trials behind most of the human evidence used epithalamin, a crude pineal-gland extract, not the four-amino-acid synthetic peptide sold as Epithalon today, and all of it comes from one Russian research group without independent Western trials. So there is solid animal and cell-culture data, but no independent confirmation in humans for the actual synthetic peptide.

No study has measured a specific onset time in humans. The Russian trial protocols ran five to ten day injection courses repeated two to three times a year for up to three years, and the lifespan gains seen in mice and rats were measured over the animals' full remaining lifespan, not after a defined interval. There is no human data on how quickly, or whether, any effect appears within a single course.

Self-administration outside any trial typically runs 5 mg a day for 20 days, or 10 mg a day for 10 days, in two to three cycles a year spaced four to six months apart — about 55 to 145 µg/kg for a 70-90 kg adult. That is circulating practice, not a research finding: no clinical trial has ever dosed the synthetic AEDG peptide sold as Epithalon. Its cell-culture telomere evidence used concentrations of 0.1 to 1 µg/ml in a dish, which has no established equivalent injected dose.

Reactivating telomerase is theoretically double-edged, since uncontrolled telomerase activity is a hallmark of cancer cells, but no published study reports epithalon causing cancer. If anything, the animal record points the other way: one aging-mouse study found a roughly six-fold lower leukemia rate, and separate studies found fewer tumors and metastases in mouse breast-cancer models, though that same aging-mouse study did not find lower overall spontaneous tumor incidence. This remains a theoretical safety question that has not been tested in long-term human studies.

Published human studies report a favorable safety profile with no serious adverse effects at standard dosing. The most common reports are mild injection-site redness or swelling, occasional headache during initial use, and drowsiness — plausibly linked to its melatonin-boosting effect and often noted as beneficial for sleep. Most of this safety data comes from Russian research institutions rather than large Western randomized trials.

No Western regulator — not the FDA, not the EMA — has approved Epithalon for human use. It has been used clinically in Russia and some CIS countries through the institute that developed it, but has not gone through a formal Western clinical-trial approval process. In most Western countries it is sold and classified as a research chemical; it is not on the WADA prohibited list and does not fall under standard controlled-substance scheduling.

The lyophilised powder keeps 6 to 12 months at 2-8 °C or 24 or more months at -20 °C, and its small size and lack of cysteine or methionine make it more stable than many peptides. Once reconstituted, the clear, colourless solution should be kept at 2-8 °C and used within 21 to 28 days; brief room-temperature exposure is tolerated, but prolonged UV light exposure is not.